AbbVie Out $5.8 Billion After Scrapping Rova-T Program

AbbVie Out $5.8 Billion After Scrapping Rova-T Program - BioSpace

- August 30, 2019

AbbVie Out $5.8 Billion After Scrapping Rova-T Program BioSpace

AbbVie announced that the Phase III MERU trial evaluating Rova-T as first-line maintenance therapy for advanced small-cell lung cancer, failed to demonstrate ...

Search This Blog

Lung Cancer

AbbVie Out $5.8 Billion After Scrapping Rova-T Program - BioSpace

Comments

Post a Comment

Popular posts from this blog

Beagles, other dogs could be used to help in early detection of lung cancers, study finds - Fox 32 Chicago

Not An Ordinary Cough: Lung Cancer Symptoms That You Might Neglect - International Business Times

Beagles, other dogs could be used to help in early detection of lung cancers, study finds - Fox 32 Chicago